Oxford Nanopore Technologies PLC
LSE:ONT
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
1.2B GBP |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
188.7B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
138.6B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
34.8B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
267.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
30B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.8B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.8B USD |
Loading...
|
Market Distribution
| Min | -1 510% |
| 30th Percentile | 0.4% |
| Median | 0.5% |
| 70th Percentile | 0.7% |
| Max | 7 323.1% |
Other Profitability Ratios
Oxford Nanopore Technologies PLC
Glance View
Oxford Nanopore Technologies PLC stands as a pioneering force in the field of genomics, transforming the landscape of DNA and RNA sequencing. Founded as a spin-off from the University of Oxford, the company gained recognition with its distinctive nanopore sequencing technology, which radically differs from traditional sequencing methods. Traditional sequencing often involves a process that can be expensive, time-consuming, and complex. However, Oxford Nanopore's approach uses tiny, porous apertures coupled with electrical signals to read genetic codes directly. This technology allows for the sequencing of long DNA strands in real-time, providing not only speed and efficiency but also the versatility to handle a wide range of samples, from environmental to clinical applications. By making sequencing more accessible and portable through their critically acclaimed MinION device, the company has managed to capture significant interest and investment from researchers across diverse scientific fields. The business model of Oxford Nanopore Technologies is built upon a strategic blend of product sales, including their sequencing devices and associated consumables, alongside providing commercial sequencing services. Their revenue streams are anchored by the MinION, GridION, and PromethION devices, each catering to varied throughput needs and scales of operation. Sales of these devices are complemented by a continuous income from consumable sales, essential for each sequencing run, which helps to embed their technology deeply within the workflows of their users. Additionally, the company's expansion into data analysis services further diversifies their income, utilizing their specialized expertise to assist customers in interpreting and utilizing complex genomic data. This multifaceted approach not only solidifies their position in the genomics market but also ensures multiple pathways for generating sustained revenue growth.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Oxford Nanopore Technologies PLC is 58.6%, which is above its 3-year median of 56.6%.
Over the last 3 years, Oxford Nanopore Technologies PLC’s Gross Margin has decreased from 62.3% to 58.6%. During this period, it reached a low of 53.3% on Dec 31, 2023 and a high of 62.3% on Dec 31, 2022.